The peculiar feature of VDT is (i) its high specificity for lymphoma and leukemia cells, (ii) its low cytotoxicity in untransformed HSPC and PBMC which offers a therapeutic window, and (iii) its proficiency to directly activate the mitochondrial apoptosis pathway even in the presence of Bcl-2 which enables overcoming of therapy resistance in hematological neoplasia that express antiapoptotic Bcl-2 proteins. The gene discussed is BCL2; the disease is lymphoma.